key: cord-0904677-0f80pdmf
authors: Fahim, Peter; Nicolaysen, Anthony; Yabu, Julie M.; Zuckerman, Jonathan E.
title: Osmotic Tubulopathy and Acute Thrombotic Microangiopathy in a Kidney Transplant Recipient With a Breakthrough COVID-19 Infection
date: 2022-05-26
journal: Kidney Med
DOI: 10.1016/j.xkme.2022.100492
sha: 3774890b2ea6f435d998f995f06960233aae7b71
doc_id: 904677
cord_uid: 0f80pdmf

Acute kidney injury (AKI) is a known complication of SARS-CoV-2 infection for which many different pathophysiological processes have been reported. Here, we present a case of a 45-year-old kidney transplant recipient with a breakthrough coronavirus disease 2019 (COVID-19) infection complicated by an episode of AKI 26 months post-transplant. She had minimal respiratory symptoms, pancytopenia, mild hematuria, and proteinuria. A kidney biopsy revealed acute thrombotic microangiopathy (TMA) as well as an osmotic tubulopathy. The TMA was favored to be secondary to COVID-19 infection as other etiologies for TMA such as acute calcineurin inhibitor toxicity and acute antibody mediated rejection were excluded. The osmotic tubulopathy was favored to be secondary to remdesivir therapy; specifically related to the sulfobutylether-b-cyclodextrin (SBECD) solubilizing carrier agent used in its formulation. The patient’s kidney function improved following resolution of the COVID-19 infection. This case illustrates a unique occurrence of kidney injury secondary to COVID-19 infection and anti-COVID-19 therapy.

Kidney injury is a prominent component of the clinical spectrum of coronavirus disease 2019 . There are widely disparate reported rates of acute kidney injury (AKI) among hospitalized patients with COVID-19, ranging from 0.5% to 37%. 1 AKI appears to involve a complex process driven by virus-mediated injury, cytokine storm, angiotensin II pathway activation, dysregulation of complement, hypercoagulation, and microangiopathy interacting with common and known risk factors for AKI. Patients with COVID-19 can also develop glomerular pathologies .2,3 Moreover, novel antiviral pharmaceuticals are in use, and their potential for kidney toxicity has yet to be fully explored. We report a case of osmotic injury associated with antiviral therapy, another reported pattern of tubular pathology related to COVID-19.

A 45-year-old woman with kidney failure secondary to collapsing glomerulopathy received a living unrelated kidney transplant, which was complicated by acute cellular rejection one month post-transplant treated with IV methylprednisolone.

Immunosuppression medications were tacrolimus 3 mg twice daily, mycophenolate mofetil (MMF) 750 mg twice daily, and prednisone 5 mg daily. Her medical history was also significant for normocytic anemia (attributed to chronic kidney disease and There were no double contours or viral particles. There were segmental small mesangial electron dense deposits. Peritubular capillary basement membranes were normal.

The kidney biopsy interpretation was acute thrombotic microangiopathy (TMA), acute tubular injury with osmotic tubulopathy, and low grade glomerular C3 deposition, possibly infection related.

Additional diagnostic testing for etiologies for thrombotic microangiopathy was obtained: ADAMTS13 activity 118% (reference value >=67), haptoglobin 10 mg/dL (reference range 21-210 mg/dL), C3 91 mg/dL (reference range 76-165 mg/dL) C4 37 mg/dL (reference range 14-46 mg/dL), and complement activity alternative pathway 136 % (reference range > 59%). Peripheral smear did not show schistocytes.

During her hospitalization, tacrolimus dose was adjusted due to supratherapeutic tacrolimus level attributed to CYP3A4 inhibition by remdesivir. The patient's kidney J o u r n a l P r e -p r o o f function started to improve on hospital day 9. Serum creatinine prior to discharge was 5.91 mg/dL and 3.34 mg/dL one week after discharge. Most recent serum creatinine was 3.42 mg/dl, which was two months after her admission.

TMA associated with COVID-19 has been previously reported. 2 Evidence suggests SARS-CoV-2 leads to cytokine storm-mediated kidney injury through activation of the alternative pathway of the complement rather than direct viral infection of the kidney. 4 The presence of low grade C3 deposition within the glomerulus seen in this case may further implicate the alternative complement activation or possibly a concurrent low grade infection related glomerulopathy. Interestingly, COVID-19 associated kidney diseases including TMA often occur even with mild pulmonary and systemic COVID-19 disease. 2 Etiologies for TMA are diverse and there are no specific findings on kidney biopsy that can discriminate among them. Alternative differential diagnoses for TMA in this case include tacrolimus-induced TMA and active antibody mediated rejection (AMR). The patient's tacrolimus trough was in the 7-9 ng/ml range for at least one year prior to presentation and serum creatinine was stable until the COVID-19 infection. The patient also had multiple prior allograft biopsies without evidence of acute or chronic tacrolimus effects. Tacrolimus trough three days prior to presentation was 7.1 ng/ml and the thrombocytopenia was improving during her hospital stay despite development of slightly supratherapeutic tacrolimus trough levels. Thus, tacrolimus-induced TMA is a less likely etiology for the patient's acute kidney injury or pathologic findings. As this patient had no other evidence for antibody mediated rejection (e.g., no microvascular J o u r n a l P r e -p r o o f inflammation, C4d negative, or serum donor specific antibodies), the possibility of AMR associated TMA was thought to be unlikely.

Other less likely etiologies of TMA such ADAMTS13 deficiency, other infections, antiphospholipid antibodies, and drug associated TMA were also ruled out. An underlying complement mediated TMA with COVID-19 as a trigger is also a possibility; however, more extensive complement system evaluation (e.g., genetic studies) was not performed as the patient's kidney function improved after COVID-19 resolution.

Osmotic tubulopathy describes a morphological pattern with vacuolization and swelling seen when proximal tubules are overwhelmed by a load of indigestible carbohydrates. Injury is favored to be due to pinocytosis with uptake into lysosomes. 5 Osmotic tubulopathy is generally associated with mannitol, low-molecular-weight dextrans, intravenous radiologic contrast media, hydroxyethyl starch, excess glucose, methanol, and gelatin. 6 Our patient did not receive any of these agents. The patient's blood glucose was normal or near normal and urine glucose was negative at time of admission. Additionally, no reports suggest that Casirivimab/Imdevimab causes AKI, tacrolimus interaction or pathologic changes on kidney biopsy and it has been tolerated by kidney transplant patients. 7, 8 Remdesivir is a nucleotide analog that inhibits viral RNA-dependent RNA polymerase (RdRp). 9 Remdesivir formulation contains sulfobutylether-b-cyclodextrin (SBECD) as a solubilizing carrier agent, and we postulate that this contributed to osmotic tubulopathy in our patient. At least one prior case of remdesivir osmotic tubulopathy has been reported. 10 SBECD is a large, cyclic oligosaccharide that is predominantly excreted through glomerular filtration. 11 Preclinical animal study suggested that reversible J o u r n a l P r e -p r o o f cytosolic vacuolation in kidney tubular epithelial cells was observed at as low as 160 mg/kg in rats. 10 Each 100 mg of lyophilized powder and solution of remdesivir contain 3 and 6 g of SBECD, respectively, and our patient received a total of 600 mg of the lyophilized form of remdesivir. The use of remdesivir with decreased kidney function is relatively safe. Although 11.7 % of kidney transplant recipients reported elevated serum creatinine following remdesivir therapy, none required discontinuation of therapy. 12 The primary differential diagnoses of the tubular vacuolar change seen in this case is CNI toxicity, which is characterized by isometric vacuolization and may be indistinguishable from osmotic tubulopathy. The tubular cytoplasmic vacuolization observed in our case was diffuse and variably coarse which is not typical for acute CNI toxicity which usually shows focal fine isometric vacuolization. Other convincing morphologic features of CNI nephrotoxicity (e.g., myocyte cytoplasmic vacuolization and dropout, focal nodular hyalinosis) were not present 13 Thus, we believe the osmotic tubulopathy was mostly likely due to remdesivir therapy. Interestingly, remdesivir is a weak CYP3A4 inhibitor that may lead to increased tacrolimus levels and could explain the slightly supratherapeutic tacrolimus trough levels that developed during the patient's admission. 14 In summary, the patient's clinical course and kidney biopsy support that this patient's AKI was most likely secondary to a COVID-19 associated TMA possibly exacerbated by an osmotic tubulopathy secondary to remdesivir therapy. This case illustrates that severe COVID-19 associated kidney disease can occur even with an otherwise mild COVID-19 infection, and that novel treatments such as remdesivir may result in renal biopsy histologic perturbations. 

Coronavirus Disease 2019 and Acute Kidney Injury: What Have We Learned?

Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria

A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney International

Covid-19 and kidney injury: Pathophysiology and molecular mechanisms

Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report

Osmotic Nephrosis: Acute Kidney Injury With Accumulation of Proximal Tubular Lysosomes Due to Administration of Exogenous Solutes

Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience

Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients

Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis

Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir

Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

AJKD Atlas of Renal Pathology: Calcineurin Inhibitor Nephrotoxicity

SARS-CoV-2 infection increases tacrolimus concentrations in solid-organ transplant recipients

Abs, absolute; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CMV, cytomegalovirus; CRP, C-Reactive protein; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; PTT-INR, prothrombin time and international normalized ratio; TSH, thyroid stimulating hormone